- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04450953
The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients. (EVATRAN)
A Randomized Crossover Clinical Trial Regarding the Blockage of the Mineralocorticoid Receptor Using Eplerenone on the Evolution of Arterial Stiffness in Kidney Patients One Year After Transplant
Cardiovascular (CV) pathologies are the leading cause of death in kidney transplant patients.Arterial stiffness is a prognostic factor for CV mortality in kidney transplantation. Despite a reduced CV risk in transplant kidney patients in comparison to patients in dialysis, CV mortality among kidney transplant patients is much higher than the general population.
After renal transplantation, the cardiac and vascular anomalies observed in chronic end-stage renal disease are partially improved because of restored normal kidney function and withdrawal from dialysis.
However, patients are exposed to immunosuppressive drugs, in particular calcineurin inhibitors, which can be associated with vascular toxicity, either directly or by promoting the appearance of hypertension, diabetes, or dyslipidemia.The pathophysiology of arterial stiffness in kidney transplantation is complex and multifactorial.
Calcineurin inhibitors are likely to play an important role in the persistence of increased arterial stiffness in transplant patients in whom renal function has been restored. Indeed, the discontinuation of anti-calcineurins in favour of other molecules .is associated with a decrease of arterial stiffness.
Preclinical work has shown that the vascular toxicity of cyclosporine is mediated by activation of the mineralocorticoid receptor in smooth muscle cells. The involvement of the mineralocorticoid receptor in the onset of arterial stiffness is also well demonstrated in non-transplanted subjects.
Blocking the mineralocorticoid receptor in patients under cyclosporine may reduce their arterial stiffness and in and consequently improve their CV prognosis.
Studies have show a good safety in kidney transplant patients. This pilot study proposes to examine, for the first time, the impact of treatment with a mineralocorticoid receptor antagonist on the evolution of arterial stiffness in renal transplant patients on calcineurin inhibitors.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sophie GIRERD, MD-phD
- Phone Number: +33 (0) 3 83 15 73 22
- Email: s.girerd@chru-nancy.fr
Study Locations
-
-
-
Vandœuvre-lès-Nancy, France, 54500
- Recruiting
- CHRU de Nancy
-
Contact:
- Sophie GIRERD, MD
- Phone Number: +33 (0) 3 83 15 73 22
- Email: s.girerd@chru-nancy.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women ≥ 50 years of age;
- Patient who had a kidney transplant at least one year prior to inclusion;
- Patient on cyclosporine;
- Patient whose clinical-biological state has been stable for at least 3 months: no change in treatment with an impact on blood pressure (excluding immunosuppressive drug) for 3 months, no acute rejection diagnosed within 3 months;
- Patient with a glomerular filtration rate estimated according to the formula CKD-EPI ≥30mL/min/1.73m2;
- Patient with a peripheral PAS≥110mmHg, irrespective of the presence or not of an antihypertensive therapy (including ACE inhibitors or sartan) ;
- Patient with signed informed consent;
- Patient affiliated with or beneficiary of a social security system.
Exclusion Criteria:
- Patient with documented kalemia ≥ 5mmol/L in the last 15 days;
- Patient undergoing mineralocorticoid receptor antagonism or with a formal indication to receive this treatment;
- Bicarbonate blood level <20mmol/L with or without documented supplementation in the last 15 days.
- Indication for a combination of ACE inhibitor and sartan (each of which is authorized separately);
- Patient under another potassium sparing diuretics;
- Patient under digoxine;
- Sodium polystyrene sulfonate contraindication;
- Known hypersensitivity or allergy to eplerenone and its excipients;
- Patient with severe hepatic impairment (Child-Pugh Class C);
- Patient under CYP3A4 inhibitor;
- know intolerance to Galactose, a Lapp lactase deficiency or galactose malabsorption syndrome;
- Patient participating in other interventional research;
- Woman with a desire of pregnancy within 15 months;
- Woman of childbearing age without effective contraception;
- Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code :
- Pregnant women, parturient women or nursing mothers ;
- Adult person subject to a legal protection measure (guardianship, curator, judicial safeguard);
- Adults person who is unable to give consent and who is not subject to a legal protection measure;
- Persons deprived of their liberty by a judicial or administrative decision;
- Persons subject to psychiatric care pursuant to articles L. 3212-1 and L. 3213-1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Eplerenone group A (cross over design)
Patient will receive eplerenone 50mg/day taken orally for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period without eplerenone, until the end of the study.
|
Eplerenone 50mg/day for 6 months followed
6-month period without eplerenone
|
Active Comparator: Eplerenone group B (cross over design)
Eplerenone-free for 6 months, followed by a 8 to 10 weeks wash-out period, then a 6-month period in which patients will receive eplerenone 50 mg/day as a single dose taken orally.
|
Eplerenone 50mg/day for 6 months followed
6-month period without eplerenone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evolution of pulse wave velocity (PWV in m/s) adjusted to the blood pressure
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of Central Systolic Blood Pressure (CSPc)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of central Diastolic Blood Pressure (CDAb)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of Central Pulsed Pressure (CPp)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of Augmentation index (Aix in %)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution peripheral systolic blood pressure (PASp in mmHg)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of peripheral diastolic blood pressure (PADp in mmHg)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of peripheral pulse pressure (PPp in mmHg)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of Intima-media thickness (in mm)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of left ventricular mass (LVM in g/m2)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of biological markers of oxidative stress (plasma Isoprostane)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of biological markers of oxidative stress (Malondialdehyde)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of Biological markers of endothelial dysfunction (endothelin)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of biological markers of endothelial dysfunction (soluble endothelium selectin (sE-selectin))
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of biological markers of endothelial dysfunction (von Willebrand factor)
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Evolution of graft function
Time Frame: After 6 months of treatment with eplerenone
|
measured by creatinine (in micromol/L) with estimation of glomerular filtration rate (eGFR in mL/min/1.73m2
) according to the CKD-EPI formula.
|
After 6 months of treatment with eplerenone
|
Evolution of proteinuria
Time Frame: After 6 months of treatment with eplerenone
|
measured by the ratio proteinuria/creatinuria (in mg/g)
|
After 6 months of treatment with eplerenone
|
Percentage of patients with DFG ≥ 90, 60-89, 45-59, 30-44, 15-29 <15ml/min/1,73m2
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
Percentage of patient with ratio proteinuria/creatinuria (en mg/g) <500 ; 500-1000, 1000-2000, 2000-3000, >3000
Time Frame: After 6 months of treatment with eplerenone
|
After 6 months of treatment with eplerenone
|
|
hyperkalemia occurence ≥ 5.5 mmol/L
Time Frame: during 6 month of treatment with eplerenone
|
during 6 month of treatment with eplerenone
|
|
Number of hyperkalemia
Time Frame: during 6 month of treatment with eplerenone
|
number of hyperkalemias during hyperkalemia follow-up between 5 - 5.49; 5.5 - 6; >6mmol/L
|
during 6 month of treatment with eplerenone
|
increase of creatinine of more than 50%
Time Frame: during 6 month of treatment with eplerenone
|
Evaluation of risk of acute renal failure defined as an increase in creatinine of more than 50%
|
during 6 month of treatment with eplerenone
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Nicolas GIRERD, MD-Phd, Central Hospital, Nancy, France
- Principal Investigator: Sophie GIRERD, MD-PhD, Central Hospital, Nancy, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-004243-74
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation for More Than One Year
-
Grigore T. Popa University of Medicine and PharmacyCompletedPatients on Hemodialysis for More Than 3 MonthsRomania
-
Assistance Publique - Hôpitaux de ParisCompletedMinor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been PerformedFrance
-
University Hospital, Clermont-FerrandGroupe Hospitalier Pitie-SalpetriereCompletedAdult Patients Ventilated More Than 48 h | Stable Respiratory and Hemodynamic Conditions for SBT | Consent of Patients | Arterial LineFrance
-
Seoul National University HospitalCompletedPatients Who Had the Urine Volume at Nighttime More Than One Third of Total Daily Urine Volume (NPU) and Voided More Than Two Times at Nighttime (Nocturia)Korea, Republic of
-
Helsinki University Central HospitalRecruitingMedial Epicondyle Fracture of the Humerus | 7 to16 Year Old Children and Adolecents | More Than 2 mm of DisplacementFinland
-
University of MonastirRecruitingPatients Hospitalized for More Than 48 Hours | Acute Medical IllnessTunisia
-
University Hospital, RouenRecruitingPatients With Chronic Pruritus for More Than 1 Month Who Have Received ImmunotherapyFrance
-
University Hospital, Clermont-FerrandPitié-Salpêtrière HospitalCompletedAdult Patients Ventilated More Than 48 h | Stable Respiratory and Hemodynamic Conditions for SBT | Consent of Patients | Arterial LineFrance
-
Novartis PharmaceuticalsWithdrawnPatients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
-
University Hospital, MontpellierTerminatedChronic Respiratory Failure With Acute Decompensation Requiring Mechanical Ventilation for More Than 48 HoursFrance
Clinical Trials on Eplerenone 50mg/day (cross over design)
-
Rigshospitalet, DenmarkTrygFonden, DenmarkCompletedRapid Sequence IntubationDenmark
-
Merck Sharp & Dohme LLCCompleted
-
AstraZenecaActive, not recruitingAnticancer TreatmentUnited States, France, Germany, Spain, Sweden, United Kingdom, Canada, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, China, Taiwan, Hong Kong, Netherlands, Australia, Mexico
-
Universitaire Ziekenhuizen KU LeuvenVU University of AmsterdamCompleted
-
SanofiRecruitingTransplant RejectionGermany, Italy, Spain, United States, Canada, France, Sweden
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited States, Croatia, Mexico, Poland, Ukraine
-
Memorial Sloan Kettering Cancer CenterCompletedNon-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain CancerUnited States